Pfizer’s RSV Maternal Vaccine Candidate BLA Accepted by FDA for Priority Review
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine…
Read More...
Read More...
